Published in

Elsevier, Leukemia Research, 7(38), p. 816-821, 2014

DOI: 10.1016/j.leukres.2014.04.002

Links

Tools

Export citation

Search in Google Scholar

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

Journal article published in 2014 by Christen Lykkegaard Andersen, Mads Emil Bj, Mads Emil Bjørn, Mary Frances McMullin, Claire Harrison, Jan Samuelsson, Elisabeth Ejerblad, Sonja Zweegman, Savio Fernandes, David Bareford, Steven Knapper, Eva Löfvenberg, Olle Linder, Bj Andreasson, Erik Ahlstrand and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P